Facet Biotech clinical trials

Formerly part of Abbott, Jan 1, 2013 · source ↗

The registry lists 17 studies whose lead sponsor is Facet Biotech. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2013.

Studies

Recruiting first, then most recently updated. Showing 17 of 17. All Abbott studies →

• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous LeukemiaStatus unknownNCT00006045Phase 3

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal CancerTerminatedNCT00516841Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With HypertensionWithdrawnNCT00528827Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Research Study of Visilizumab for Treatment of Acute Graft Versus Host DiseaseCompletedNCT00032292Phase 1/2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's DiseaseCompletedNCT00072943Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Study of Daclizumab in Patients With Chronic, Persistent AsthmaCompletedNCT00028288Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisTerminatedNCT00279422Phase 2/3

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyTerminatedNCT00279435Phase 2/3

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative ColitisCompletedNCT00267306Phase 1/2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Pilot Study in Patients With Symptomatic Steroid-Naive AsthmaCompletedNCT00024544Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's DiseaseCompletedNCT00267722Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Visilizumab for Treatment of Perianal Fistulas in Crohn's DiseaseCompletedNCT00267709Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Research Study in Patients With Severe Ulcerative ColitisCompletedNCT00032305Phase 2/3

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaCompletedNCT00425347Phase 1

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart FailureWithdrawnNCT00487799Phase 1

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative ColitisCompletedNCT00073047Phase 2

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisWithdrawnNCT00502294Phase 3

  Sponsor listed in the registry: Facet Biotech · First submitted before Facet Biotech left Abbott